Document is current

Article History

Received: 15 May 2024

Accepted: 1 October 2024

First Online: 7 October 2024

Declarations

:

: The PALLAS trial was approved by institutional review boards and ethics committees. All patients included in this analysis provided written informed consent, and the trial was performed in strict accordance with International Conference on Harmonisation – Good Clinical Practice (ICH-GCP) guidelines.

: Not applicable.

: GN-M reports travel support from AstraZeneca. CS has served as a consultant for Novartis and AstraZeneca; and received grant support from Daiichi-Sankyo and Amgen. DH reports research grants from Pfizer to the institution. AD received institutional research support from Novartis, Pfizer, Genentech, and Neogenomics; and reports that her spouse received support from Pfizer DSMB for a non-oncology trial. PT received institutional research support from AstraZeneca; and served in a consultant or advisory role for AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Roche, Genentech, Menarini/Stemline, and Novartis. EdA received honoraria from, and/or served on the advisory boards of, Roche/GNE, Novartis, Seagen, Zodiac, Libbs, Pierre Fabre, Lilly, Astra-Zeneca, MSD, and Gilead Sciences; received travel grants from Roche/GNE and AstraZeneca; received a research grant to his institution from Roche/GNE, AstraZeneca, GSK/Novartis, and Gilead Sciences; and served as ESMO director of Membership from 2023–2025 and BSMO President from 2023–2026. GP received honoraria and grants from Pfizer, AstraZeneca, Daiichi-Sankyo, Novartis, Amgen, Roche, Seagen, Accord, and MSD. MM received research grants from Roche, PUMA and Novartis; consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi Sankyo, Menarini/Stemline, and Pfizer; and speakers’ honoraria from AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer. JMB receives research support from Genentech/Roche and Incyte Corporation; has received advisory board payments from AstraZeneca and Mallinckrodt; and is an inventor on patents regarding immunotherapy targets and biomarkers in cancer. MB served in a consulting or advisory role for Amgen, AstraZeneca, Daiichi-Sankyo/AstraZeneca, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Samsung, Gilead Sciences, and Seagen; served on the Speakers’ Bureaus of Amgen, AstraZeneca, Daiichi-Sankyo/AstraZeneca, Lilly, Novartis, Pierre Fabre, Pfizer, Roche, and Seagen; received institutional research funding from Lilly, Novartis, Pfizer, and Pierre Fabre; and received support for travel, accommodations and expenses from MSD. AMB served as a consultant for AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, Seagen, Daiichi-Sankyo, Merck, Agendia, Sanofi, Puma, Myriad, Gilead, Epic Biosciences, Blueprint, Caris, and Tempus. PGM received honoraria from Pfizer, AstraZeneca, Genomic Health, Novartis, Seagen, Gilead Sciences, and Roche; played a consulting or advisory role for Novartis; received research funding from Teva and Genomic Health (to the institution); and received support for travel, accommodations and expenses from Roche/Genentech. TCH received institutional grant funding from Takeda Oncology; and consulting fees to the institution from Puma Biotechnology. SL received grants and other from Abbvie, AstraZeneca, Celgene, Daiichi-Sankyo, Immunomedics/Gilead, Novartis, and Pfizer; other from Amgen, BMS, EirGenix, Eisai Europe Ltd, GSK, Lilly, Merck KG, Relay Therapeutics, Sanofi, and Olema Pharmaceutics (outside the submitted work); grants from Molecular Health; grants, non-financial support and other from Roche; non-financial support and other from Seagen, other from Olema Pharmaceutics, outside the submitted work; and has a patent VM Scope with royalties paid, a patent EP14153692.0 pending, a patent EP21152186.9 pending, and a patent EP15702464.7 pending. YL is a Pfizer employee and owns Pfizer stocks. LS and CF report research grants from Pfizer to the institution. ELM reports a consulting or advisory role for Lilly, Novartis, and AstraZeneca; and is an associate editor for Breast Cancer Research. MG reports personal fees/travel support from Amgen, AstraZeneca, Daiichi-Sankyo, Eli Lilly, EPG Health (IQVIA), Menarini-Stemline, MSD, Novartis, Pierre Fabre, and Veracyte; and an immediate family member who is employed by Sandoz. All remaining authors have declared no conflicts of interest.